" class="no-js "lang="en-US"> Bruno Larvol - Medtech Alert
Friday, March 31, 2023

Breaking News

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
Bruno Larvol

Bruno Larvol

About Bruno Larvol

Founder of LARVOL, a VR-first, remote-always organization of 170+ professionals providing SaaS solutions to 15 Fortune 500 healthcare and pharmaceutical companies. LARVOL aims to grow into the most interesting $100 M business.

Related Story

Diseases

 LARVOL Launches the First Cancer-Focused Social Listening Platform for Pharma and Oncology | Pharmtech Focus

LARVOL Launches Cancer-Focused Social Listening Platform

April 14 2021

LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today […]